Related Experiment Video
Updated: Feb 26, 2026
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
8.2K
Emerging biologic targets in type 2 and non-type 2 asthma.
Andrea E Davis1,2, Sarah Rhoads2, Michael E Wechsler2
1Division of Pulmonary, Allergy and Critical Care Medicine, the Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora.
Current Opinion in Pulmonary Medicine
|February 24, 2026
Summary
Novel therapies aim to achieve remission in severe asthma by targeting new pathways and using advanced drug delivery. Current biologics improve symptoms but often fall short of complete remission due to asthma
Area of Science:
- Pulmonology and Respiratory Medicine
- Pharmacology and Drug Development
Background:
- Severe asthma remains a major global health challenge, contributing significantly to morbidity and mortality.
- Despite advancements in asthma management over the last two decades, achieving complete remission in severe cases remains elusive for many patients.
Purpose of the Study:
- To review novel therapeutic agents and strategies under investigation for severe asthma management.
- To explore new targets and mechanisms aimed at enabling patients with severe asthma to achieve remission.
Main Methods:
- Review of current and emerging drug development strategies for severe asthma.
- Identification of novel therapeutic targets including bruton tyrosine kinase, OX-40 ligand, janus kinase, CC-chemokine receptor 4 (CCR4), and GATA-3.
- Analysis of new approaches such as ultra-long-acting formulations and combination biologic therapies.
Main Results:
- Current asthma biologics have significantly improved symptom control, quality of life, and reduced systemic steroid use for many patients.
- Novel drug development strategies include ultra-long-acting mechanisms, combination biologics, oral therapies, and targeting of new pathways.
- Emerging targets for severe asthma treatment encompass bruton tyrosine kinase, OX-40 ligand, janus kinase, CCR4, and GATA-3.
Conclusions:
- While existing biologics offer substantial benefits, they often fail to induce remission due to limitations in addressing asthma's complex pathophysiology.
- A diverse range of novel therapeutic mechanisms and targets are being actively investigated to overcome current treatment limitations.
- Future research focuses on innovative approaches to achieve sustained remission and improved long-term outcomes for severe asthma patients.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
01:26Asthma-II: Pathophysiology and Classification
4.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K
01:20Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
51
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51